Eisai Launches Leqembi Iqlik for At-Home Alzheimer’s Treatment in US

The launch follows FDA approval granted on July 13 and marks a significant shift in how patients manage the early stages of the disease. By transitioning from clinic-based IV therapy to a 500 mg weekly dose delivered via two 250 mg injections, patients can integrate their treatment into daily life without frequent hospital visits. Each injection takes approximately 15 seconds to complete, providing a more flexible alternative to clinical infusions.

Despite the shift in delivery method, safety protocols remain rigorous. Patients must still undergo MRI monitoring to check for amyloid-related imaging abnormalities (ARIA) before starting the therapy and at designated intervals throughout the treatment course. BioArctic, the Swedish biopharma company behind the original discovery of lecanemab, continues to work alongside its partner Eisai to expand the drug's global footprint, which now spans 53 countries.